Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois.
Department of Radiation Oncology, The Ohio State University, Columbus, Ohio.
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):306-312. doi: 10.1016/j.ijrobp.2016.10.010. Epub 2016 Oct 19.
Pelvic bone marrow (BM) constraints may offer a means to reduce the toxicity commonly associated with chemoradiation for anal cancer. We conducted a bi-institutional analysis of dose-volume metrics in a time-sensitive fashion to devise practical metrics to minimize hematologic toxicity.
Fifty-six anal cancer patients from 2 institutions received definitive radiation therapy (median primary dose of 54 Gy) using intensity modulated radiation therapy (IMRT, n=49) or 3-dimensional (3D) conformal therapy (n=7) with concurrent 5-fluorouracil (5-FU) and mitomycin C. Weekly blood counts were retrospectively plotted to characterize the time course of cytopenias. Dose-volume parameters were correlated with blood counts at a standardized time point to identify predictors of initial blood count nadirs.
Leukocytes, neutrophils, and platelets reached a nadir at week 3 of treatment. Smaller volumes of the pelvic BM correlated most strongly with lower week 3 blood counts, more so than age, sex, body mass index (BMI), or dose metrics. Patients who had ≥750 cc of pelvic BM spared from doses of ≥30 Gy had 0% grade 3+ leukopenia or neutropenia at week 3. Higher V40 Gy to the lower pelvic BM (LP V40) also correlated with cytopenia. Patients with an LP V40 >23% had higher rates of grade 3+ leukopenia (29% vs 4%, P=.02), grade 3+ neutropenia (33% vs 8%, P=.04), and grade 2+ thrombocytopenia (32% vs 7%, P=.04) at week 3. On multivariate analysis, pelvic BM volume and LP V40 remained associated with leukocyte count, and all marrow subsite volumes remained associated with neutrophil counts at week 3 (P<.1).
Larger pelvic BM volumes correlate with less severe leukocyte and neutrophil nadirs, suggesting that larger total "marrow reserve" can mitigate cytopenias. Sparing a critical marrow reserve and limiting the V40 Gy to the lower pelvis may reduce the risk of hematologic toxicity.
骨盆骨髓(BM)的限制可能为减少肛门癌放化疗常见的毒性提供一种手段。我们通过对剂量-体积指标进行双机构的即时分析,设计了实际的指标来最小化血液毒性。
来自 2 个机构的 56 例肛门癌患者接受了根治性放射治疗(原发剂量中位数为 54Gy),其中 49 例采用调强放疗(IMRT),7 例采用三维(3D)适形放疗,同时接受氟尿嘧啶(5-FU)和丝裂霉素 C 治疗。回顾性地绘制每周的血细胞计数,以描述细胞减少的时间过程。在标准化时间点将剂量-体积参数与血细胞计数相关联,以确定初始血细胞计数最低点的预测因子。
白细胞、中性粒细胞和血小板在治疗的第 3 周达到最低点。与年龄、性别、体重指数(BMI)或剂量指标相比,骨盆 BM 的较小体积与较低的第 3 周血细胞计数相关性更强。骨盆 BM 免于接受≥30Gy 剂量的患者,其≥750cc 体积的患者在第 3 周时白细胞减少或中性粒细胞减少的发生率为 0%。较低骨盆(LP)的 V40Gy 也与细胞减少相关。LP V40>23%的患者,白细胞减少(29% vs. 4%,P=.02)、中性粒细胞减少(33% vs. 8%,P=.04)和血小板减少(2% vs. 7%,P=.04)的发生率更高在第 3 周。多变量分析显示,骨盆 BM 体积和 LP V40 与白细胞计数相关,所有骨髓亚区体积与第 3 周的中性粒细胞计数相关(P<.1)。
较大的骨盆 BM 体积与白细胞和中性粒细胞减少的严重程度降低相关,这表明更大的总“骨髓储备”可以减轻细胞减少症。保留关键的骨髓储备并将 V40Gy 限制在下骨盆,可能会降低血液毒性的风险。